http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 09:00:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html <p>Guided Therapeutics, Inc. (OTCQB: GTHP) has filed the clinical trial results for its LuViva Advanced Cervical Scan device with the U.S. Food and Drug Administration as part of a Premarket Approval Application.</p> <p>The multicenter study, developed in coordination with the FDA, enrolled 480 women referred to biopsy due to abnormal Pap and/or HPV tests. Of the 428 women who completed the study, 99 were determined by independent pathology to have significant cervical disease. The company said 32 of those cases, or 32.3%, went undetected by the current standard of care, colposcopy-directed biopsy.</p> <p>According to the press release, LuViva detected 21 of those http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html Tue, 16 Jun 2026 09:00:37 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html <p>Guided Therapeutics, Inc. (OTCQB: GTHP) has filed the clinical trial results for its LuViva Advanced Cervical Scan device with the U.S. Food and Drug Administration as part of a Premarket Approval Application.</p> <p>The multicenter study, developed in coordination with the FDA, enrolled 480 women referred to biopsy due to abnormal Pap and/or HPV tests. Of the 428 women who completed the study, 99 were determined by independent pathology to have significant cervical disease. The company said 32 of those cases, or 32.3%, went undetected by the current standard of care, colposcopy-directed biopsy.</p> <p>According to the press release, LuViva detected 21 of those http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html Tue, 16 Jun 2026 09:00:37 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html <p>Guided Therapeutics, Inc. (OTCQB: GTHP) has filed the clinical trial results for its LuViva Advanced Cervical Scan device with the U.S. Food and Drug Administration as part of a Premarket Approval Application.</p> <p>The multicenter study, developed in coordination with the FDA, enrolled 480 women referred to biopsy due to abnormal Pap and/or HPV tests. Of the 428 women who completed the study, 99 were determined by independent pathology to have significant cervical disease. The company said 32 of those cases, or 32.3%, went undetected by the current standard of care, colposcopy-directed biopsy.</p> <p>According to the press release, LuViva detected 21 of those http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html Tue, 16 Jun 2026 09:00:37 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html <p>Guided Therapeutics, Inc. (OTCQB: GTHP) has filed the clinical trial results for its LuViva Advanced Cervical Scan device with the U.S. Food and Drug Administration as part of a Premarket Approval Application.</p> <p>The multicenter study, developed in coordination with the FDA, enrolled 480 women referred to biopsy due to abnormal Pap and/or HPV tests. Of the 428 women who completed the study, 99 were determined by independent pathology to have significant cervical disease. The company said 32 of those cases, or 32.3%, went undetected by the current standard of care, colposcopy-directed biopsy.</p> <p>According to the press release, LuViva detected 21 of those http://www.streetinsider.com/FDA/GUIDED+THERAPEUTICS+files+cervical+cancer+device+clinical+report+with+FDA/26651399.html Tue, 16 Jun 2026 09:00:37 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, announced today it had filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA). </p><p> The study protocol was developed through interactions with FDA and enrolled 480 women referred to biopsy because of abnormal Pap and/or HPV tests. Of the 428 women that completed the study, 99 were determined by expert independent pathology to have significant cervical disease that can http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Files+Premarket+Approval+Application+Clinical+Report+with+FDA/26651348.html Tue, 16 Jun 2026 09:00:00 -0400 A.06822034 GTHP O.00172307 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+31/26503212.html si-local-file:///var/storage/secattach/20260515/26503212.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+31/26503212.html Fri, 15 May 2026 13:18:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+31/26503212.html si-local-file:///var/storage/secattach/20260515/26503212.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+31/26503212.html Fri, 15 May 2026 13:18:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Feb+25++Filed+by%3A+Blumberg+Richard+P./26436878.html si-local-file:///var/storage/secattach/20260505/26436878.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Feb+25++Filed+by%3A+Blumberg+Richard+P./26436878.html Tue, 05 May 2026 18:21:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Feb+25++Filed+by%3A+Blumberg+Richard+P./26436878.html si-local-file:///var/storage/secattach/20260505/26436878.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Feb+25++Filed+by%3A+Blumberg+Richard+P./26436878.html Tue, 05 May 2026 18:21:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Grujic+Alan/26284204.html si-local-file:///var/storage/secattach/20260407/26284204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Grujic+Alan/26284204.html Tue, 07 Apr 2026 17:11:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Grujic+Alan/26284204.html si-local-file:///var/storage/secattach/20260407/26284204.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Grujic+Alan/26284204.html Tue, 07 Apr 2026 17:11:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Imhoff+John+E/26282980.html si-local-file:///var/storage/secattach/20260407/26282980.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Imhoff+John+E/26282980.html Tue, 07 Apr 2026 15:15:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Imhoff+John+E/26282980.html si-local-file:///var/storage/secattach/20260407/26282980.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+Imhoff+John+E/26282980.html Tue, 07 Apr 2026 15:15:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+JAMES+MICHAEL+C/26282566.html si-local-file:///var/storage/secattach/20260407/26282566.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+JAMES+MICHAEL+C/26282566.html Tue, 07 Apr 2026 13:54:00 -0400 GTHP O.00172307 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+JAMES+MICHAEL+C/26282566.html si-local-file:///var/storage/secattach/20260407/26282566.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GUIDED+THERAPEUTICS+INC+++For%3A+Mar+10++Filed+by%3A+JAMES+MICHAEL+C/26282566.html Tue, 07 Apr 2026 13:54:00 -0400 GTHP O.00172307 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, provided several updates in conjunction with the Company’s 2025 10k financial report, filed on March 30, 2026. </p><p> First, preliminary analysis of the FDA clinical study data has been completed. Over 480 women participated in the multicenter trial and there were no adverse events associated with use of LuViva. Of the nearly 100 women determined by independent expert pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html Tue, 31 Mar 2026 09:00:00 -0400 GTHP O.00172307 http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, provided several updates in conjunction with the Company’s 2025 10k financial report, filed on March 30, 2026. </p><p> First, preliminary analysis of the FDA clinical study data has been completed. Over 480 women participated in the multicenter trial and there were no adverse events associated with use of LuViva. Of the nearly 100 women determined by independent expert pathology to have significant cervical disease that can http://www.streetinsider.com/Press+Releases/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html Tue, 31 Mar 2026 09:00:00 -0400 GTHP O.00172307 http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html <p> PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, a rapid and painless testing platform for cervical cancer detection based on its patented biophotonic technology, provided several updates in conjunction with the Company’s 2025 10k financial report, filed on March 30, 2026. </p><p> First, preliminary analysis of the FDA clinical study data has been completed. Over 480 women participated in the multicenter trial and there were no adverse events associated with use of LuViva. Of the nearly 100 women determined by independent expert pathology to have significant cervical disease that can http://www.streetinsider.com/Business+Wire/Guided+Therapeutics+Provides+Updates+on+FDA+Application+Study+Results%2C+2025+Earnings+Increase+and+Successful+Warrant+Offering/26246556.html Tue, 31 Mar 2026 09:00:00 -0400 GTHP O.00172307